Correlation Between SPECT/CT and IDH Mutation in Brain Glioma
Single Photon Emission Computed Tomography/Computed Tomography With Pentavalent 99mTc Dimercaptosuccinic Acid in Patients With Brain Glioma; Correlation With IDH Mutation
1 other identifier
observational
40
0 countries
N/A
Brief Summary
Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas.Pentavalent 99mTc dimercaptosuccinic acid (99mTc (V) DMSA), is a nonspecific tumor targeting SPECT radiotracer, that has been used for imaging of various tumors including lung and breast carcinoma. However, to date, scarce reports discussed the utility of DMSA-V in patients with glioma.SPECT has the advantages of being widely available and not expensive. Multiple SPECT tracers have been explored. Of them Thallium-201 and 99 mTc-MIBI are, possibly, the most extensively discussed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2022
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 23, 2022
CompletedFirst Posted
Study publicly available on registry
October 27, 2022
CompletedStudy Start
First participant enrolled
November 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2023
CompletedOctober 27, 2022
October 1, 2022
1 year
October 23, 2022
October 23, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
degree of 99mTc-DMSA (V) uptake at SPECT/CT.
measured by calculating quantitative index of 99m Tc-DMSA (V) uptake by SPECT/CT as a biomarker for IDH mutation
Baseline
Secondary Outcomes (1)
IDH mutation
Baseline
Eligibility Criteria
Glioma patients visiting the nuclear medicine unit in Assiut university hospital.
You may qualify if:
- Patients with a pathologically proven glioma.
- patients conscious to provide informed consent.
You may not qualify if:
- Pregnant women.
- severely ill patients and those with disturbed conscious level,
- patients who were judged that they cannot lie down comfortably without movement for at least 20 min..
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- researcher
Study Record Dates
First Submitted
October 23, 2022
First Posted
October 27, 2022
Study Start
November 1, 2022
Primary Completion
November 1, 2023
Study Completion
December 1, 2023
Last Updated
October 27, 2022
Record last verified: 2022-10